AnaptysBio (ANAB) AI Stock Analysis

• Market Cap: $981.85M
• Dividend Yield: N/A
• Average Volume (3M): 600.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 304.17%
• EPS Growth: 29.37%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.34
• Shares Outstanding: 27,996,964
• 10 Day Avg. Volume: 327,854
• 30 Day Avg. Volume: 600,627
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 5.85
• Enterprise Value/Gross Profit: 5.91
• Enterprise Value/Ebitda: -10.82
• 1Y Price Target: $62.86
• Price Target Upside: 73.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 55 Neutral
• Price Target: $37.00 ▲(2.27% Upside)

AnaptysBio's overall stock score is primarily impacted by its financial instability, with persistent net losses and negative equity posing significant risks. Despite strong technical indicators suggesting bullish momentum, the stock's valuation is unattractive due to negative earnings and no dividend yield. The lack of earnings call data and corporate events further limits the assessment.

Positive Factors

Business Model

AnaptysBio's partnership-based revenue model allows it to monetize its technology while sharing financial risks, providing a sustainable path for growth.

Pipeline Development

AnaptysBio's proprietary technology platform supports the development of novel therapeutics, strengthening its competitive position in biotechnology.

Strategic Separation

The strategic separation into two entities could unlock value by allowing focused management and investment strategies tailored to distinct business models.

Negative Factors

Financial Instability

Persistent financial instability with net losses and negative equity raises concerns about long-term viability and ability to fund ongoing operations.

Debt Levels

High debt levels and negative equity indicate potential solvency issues, limiting financial flexibility and increasing risk for investors.

Profitability Challenges

Ongoing profitability challenges, with negative profit margins, hinder AnaptysBio's ability to generate sustainable earnings and reinvest in growth.

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the development of novel therapeutic antibodies for the treatment of inflammatory diseases and cancer. The company leverages its proprietary SHM-XEL™ technology platform to create differentiated antibody candidates, primarily targeting immune-mediated diseases. AnaptysBio’s pipeline includes several promising candidates in various stages of clinical trials, aimed at addressing unmet medical needs in its focus areas.

How the Company Makes Money

AnaptysBio generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies. The company enters into strategic alliances that often involve upfront payments, milestone payments contingent on the achievement of specific development goals, and royalties on future product sales. Additionally, AnaptysBio may receive funding for research and development activities as part of these collaborations. This model allows the company to monetize its innovative antibody platform and pipeline candidates while sharing the financial risks associated with drug development. As of now, the company has not yet commercialized any products, so its revenue is largely dependent on these partnerships and potential future royalties.

AnaptysBio Financial Statement Overview

Summary

AnaptysBio is experiencing strong revenue growth but faces significant profitability and cash flow challenges. Despite increased revenue, the company remains unprofitable with negative margins and returns. The balance sheet shows moderate leverage and low equity levels, indicating a need to enhance profitability and cash flow.

Income Statement

AnaptysBio has experienced substantial revenue growth from $10.3M in 2022 to $111.9M TTM, indicating a strong upward trajectory. However, the company continues to operate at a loss, with a negative net profit margin of -125.7% and a negative EBIT margin of -89.7% TTM. This suggests significant profitability challenges despite revenue growth.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 0.46 TTM, indicating moderate leverage. The equity ratio stands at 8.1% TTM, reflecting a relatively low proportion of equity financing. The negative ROE of -413.2% TTM points to ongoing profitability issues impacting shareholder returns.

Cash Flow

AnaptysBio's free cash flow improved slightly from -$135.7M in 2024 to -$102.2M TTM, but remains negative, indicating cash flow challenges. The operating cash flow to net income ratio of 0.72 TTM shows that cash losses are closely aligned with accounting losses, highlighting limited cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	123.16M	91.28M	17.16M	10.29M	63.17M	75.00M
Gross Profit	121.97M	91.28M	14.78M	7.95M	-35.32M	-5.03M
EBITDA	-66.55M	-92.74M	-143.16M	-105.26M	-55.71M	-19.37M
Net Income	-132.59M	-145.23M	-163.62M	-128.72M	-57.19M	-19.92M
Balance Sheet
Total Assets	335.25M	483.83M	452.39M	610.38M	643.07M	416.55M
Cash, Cash Equivalents and Short-Term Investments	265.71M	385.37M	390.90M	441.24M	548.10M	393.65M
Total Debt	346.46M	16.04M	17.81M	19.45M	20.95M	342.00K
Total Liabilities	379.98M	412.97M	364.29M	348.28M	286.64M	19.82M
Stockholders Equity	-44.73M	70.87M	88.10M	262.10M	356.43M	396.73M
Cash Flow
Free Cash Flow	-128.08M	-135.69M	-121.61M	-73.95M	-47.29M	-14.73M
Operating Cash Flow	-127.71M	-135.34M	-120.80M	-73.59M	-45.92M	-14.16M
Investing Cash Flow	80.47M	95.40M	144.75M	-394.85M	38.84M	94.47M
Financing Cash Flow	19.71M	127.05M	-59.30M	44.02M	252.30M	-879.00K

AnaptysBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 36.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 36.18 is above the 20-day moving average (MA) of 32.79, above the 50-day MA of 25.84, and above the 200-day MA of 21.60, indicating a bullish trend. The MACD of 2.74 indicates Positive momentum. The RSI at 73.25 is Negative, neither overbought nor oversold. The STOCH value of 77.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.

AnaptysBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	―	$458.21M	48.01	3.33%	―	85820.30%	―
CMPX	―	$681.14M	―	-51.84%	―	-100.00%	-25.75%
ANAB	―	$981.85M	-8.08	―	―	304.17%	29.37%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MGTX	―	$701.50M	―	-379.53%	―	366.84%	-35.87%
OLMA	―	$551.13M	―	-49.72%	―	―	6.82%
TERN	―	$679.96M	―	-35.02%	―	―	20.37%

AnaptysBio Corporate Events

AnaptysBio Announces Business Separation Plans

On September 29, 2025, AnaptysBio announced plans to separate its business into two independent, publicly traded companies by the end of 2026. This strategic move aims to maximize shareholder value by allowing investors to align with each company’s distinct strategic and financial objectives. The separation will create a Royalty Management Company to manage substantial royalties and a Biopharma Company focused on developing and commercializing therapeutics. This decision reflects AnaptysBio’s commitment to unlocking and maximizing value for its stakeholders.

The most recent analyst rating on (ANAB) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

AnaptysBio Reports Q2 2025 Financial Results and Updates

AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in innovative immunology therapeutics for autoimmune and inflammatory diseases. The company recently released its financial results for the second quarter of 2025, highlighting significant progress in its clinical trials and collaborations.

AnaptysBio Faces Critical Risk: Potential Impact on Operations and Investor Confidence

AnaptysBio faces a significant business risk as outlined in the risk factor titled ‘3333Item’. This risk could potentially impact their operational efficiency and financial stability. External analysts suggest that the company may need to implement strategic measures to mitigate this risk effectively. Failure to address this issue could result in adverse effects on their market position and investor confidence.